氯吡格雷药物基因组学与非遗传因素研究进展

被引：4

作者：

林睿娟 ^{[1
,2
]}

马培志 ^{[1
]}

赵宁民 ^{[1
]}

机构：

[1] 郑州大学人民医院河南省人民医院药学部

[2] 郑州大学医学科学院

来源：

中国临床药理学杂志 | 2019年 / 35卷 / 16期

关键词：

氯吡格雷; 基因多态性; 微小RNA; 药物相互作用; 个体化;

D O I：

10.13699/j.cnki.1001-6821.2019.16.027

中图分类号：

R968 [遗传药理学];

学科分类号：

100706 [药理学];

摘要：

作为重要的抗血小板药物,氯吡格雷已经被纳入国家基本药物目录。然而有4%～30%的患者在常规剂量下达不到预期的抗血小板效果,出现氯吡格雷抵抗现象。氯吡格雷个体差异较大,不良反应严重,传统的给药模式已满足不了临床的需求。影响氯吡格雷药效的相关因素较多,本文从药效学和药代动力学分析药物基因组学对氯吡格雷药效的影响,总结可能的非遗传因素。

引用

页码：1816 / 1819+1829 +1829

页数：5

共 16 条

[1]

Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel [J].

Batchelor, Riley ;

Kumar, Radya ;

Gilmartin-Thomas, Julia F. M. ;

Hopper, Ingrid ;

Kemp, William ;

Liew, Danny .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (08) :780-796

[2]

Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects [J].

Neuvonen, Mikko ;

Tarkiainen, E. Katriina ;

Tornio, Aleksi ;

Hirvensalo, Paivi ;

Tapaninen, Tuija ;

Paile-Hyvarinen, Maria ;

Itkonen, Matti K. ;

Holmberg, Mikko T. ;

Karja, Vesa ;

Mannisto, Ville T. ;

Neuvonen, Pertti J. ;

Pihlajamaki, Jussi ;

Backman, Janne T. ;

Niemi, Mikko .

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (03) :341-345

[3]

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention [J].

Cavallari, Larisa H. ;

Lee, Craig R. ;

Beitelshees, Amber L. ;

Cooper-DeHoff, Rhonda M. ;

Duarte, Julio D. ;

Voora, Deepak ;

Kimmel, Stephen E. ;

McDonough, Caitrin W. ;

Gong, Yan ;

Dave, Chintan V. ;

Pratt, Victoria M. ;

Alestock, Tameka D. ;

Anderson, R. David ;

Alsip, Jorge ;

Ardati, Amer K. ;

Brott, Brigitta C. ;

Brown, Lawrence ;

Chumnumwat, Supatat ;

Clare-Salzler, Michael J. ;

Coons, James C. ;

Denny, Joshua C. ;

Dillon, Chrisly ;

Elsey, Amanda R. ;

Hamadeh, Issam S. ;

Harada, Shuko ;

Hillegass, William B. ;

Hines, Lindsay ;

Horenstein, Richard B. ;

Howell, Lucius A. ;

Jeng, Linda J. B. ;

Kelemen, Mark D. ;

Lee, Yee Ming ;

Magvanjav, Oyunbileg ;

Montasser, May ;

Nelson, David R. ;

Nutescu, Edith A. ;

Nwaba, Devon C. ;

Pakyz, Ruth E. ;

Palmer, Kathleen ;

Peterson, Josh F. ;

Pollin, Toni I. ;

Quinn, Alison H. ;

Robinson, Shawn W. ;

Schub, Jamie ;

Skaar, Todd C. ;

Smith, D. Max ;

Sriramoju, Vindhya B. ;

Starostik, Petr ;

Stys, Tomasz P. ;

Stevenson, James M. .

JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (02) :181-191

[4]

Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel [J].

Yang, Hong-Hui ;

Chen, Yan ;

Gao, Chuan-Yu .

CARDIOVASCULAR THERAPEUTICS, 2016, 34 (06) :460-467

[5]

Association of MicroRNAs and YRNAs With Platelet Function [J].

Kaudewitz, Dorothee ;

Skroblin, Philipp ;

Bender, Lukas H. ;

Barwari, Temo ;

Willeit, Peter ;

Pechlaner, Raimund ;

Sunderland, Nicholas P. ;

Willeit, Karin ;

Morton, Allison C. ;

Armstrong, Paul C. ;

Chan, Melissa V. ;

Lu, Ruifang ;

Yin, Xiaoke ;

Gracio, Filipe ;

Dudek, Katarzyna ;

Langley, Sarah R. ;

Zampetaki, Anna ;

de Rinaldis, Emanuele ;

Ye, Shu ;

Warner, Timothy D. ;

Saxena, Alka ;

Kiechl, Stefan ;

Storey, Robert F. ;

Mayr, Manuel .

CIRCULATION RESEARCH, 2016, 118 (03) :420-432

[6]

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 [J].

Yang, Yao ;

Lewis, Joshua P. ;

Hulot, Jean-Sebastien ;

Scott, Stuart A. .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (10) :1599-1617

[7]

Building the Case for Clopidogrel as a World Health Organization Essential Medicine [J].

Patel, Amisha ;

Vidula, Mahesh ;

Kishore, Sunny P. ;

Vedanthan, Rajesh ;

Huffman, Mark D. .

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2015, 8 (04) :447-451

[8]

Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans [J].

Tarkiainen, E. K. ;

Holmberg, M. T. ;

Tornio, A. ;

Neuvonen, M. ;

Neuvonen, P. J. ;

Backman, J. T. ;

Niemi, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (06) :650-658

[9]

Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population [J].

Priyadharsini, Rajendran ;

Shewade, Deepak Gopal ;

Subraja, Kumaresan ;

Ravindra, Byrappa Kempalalakshmamma ;

Umamaheswaran, Gurusamy ;

Dkhar, Steven Aibor ;

Satheesh, Santhosh ;

Sridhar, Magadi Gopalakrishna ;

Narayan, Sunil K. ;

Adithan, Chandrasekaran .

MOLECULAR BIOLOGY REPORTS, 2014, 41 (11) :7265-7271

[10]

Impact of High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Interventions.[J].Mario Leoncini;Anna Toso;Mauro Maioli;Dominick J. Angiolillo;Betti Giusti;Rossella Marcucci;Rosanna Abbate;Francesco Bellandi.JACC: Cardiovascular Interventions.2013,

← 1 2 →